Target intelligence / Profile preview

Ataxin-1-like (ATXN1L)

Target
ATXN1L
Molecular classification
Chromatin-binding factor, Protein coding gene, Transcriptional corepressor, Other (does not fit "receptor," "enzyme," "transport channel," etc.)
01

Overview

Ataxin-1-like (ATXN1L) is a chromatin-binding transcriptional corepressor protein and a paralog of Ataxin-1 (ATXN1). It enables chromatin binding and RNA binding activities and participates in the negative regulation of transcription mediated by RNA polymerase II. ATXN1L cooperates with Capicua (CIC) and ATXN1 in multimeric nuclear complexes, notably repressing Notch signaling by acting as a corepressor with CBF1. This protein plays regulatory roles in learning, memory, and social behavior, and is involved in development of the nervous system[2][3]. Unlike ATXN1, it does not encode a polyglutamine (polyQ) tract, but shares key structural domains with ATXN1 (e.g., AXH domain) important for protein-protein interactions[1][2]. While ATXN1L can suppress ATXN1-mediated cytotoxicity in spinocerebellar ataxia type 1, its primary functions are regulatory and it is not considered a direct therapeutic target[2][3]. The gene is associated with some CNS tumor types, but no approved drugs or biomarkers specifically target or monitor ATXN1L[2].

Other names
Ataxin-1-likeATXN1LBrother of ATXN1BOATBOAT1Brother of ataxin-1
02

Mechanism of action

Not applicable; no drugs directly target ATXN1L or act through its modulation

03

Biological functions

Negative regulation of transcription by RNA polymerase IIChromatin binding activityRNA binding activityRepression of Notch signaling (in absence of NICD) by acting as a CBF1 corepressorRegulation of learning and memoryRegulation of social behaviorBrain development, likely in concert with Capicua (CIC) and ATXN1
04

Disease associations

Neurodegenerative disease (modifier of spinocerebellar ataxia type 1 toxicity)Cancer (potentially through chromatin and transcriptional regulation)Central nervous system sarcomaEwsr1-negative small round cell tumorImmunomodulation, possibly influencing multiple sclerosis (indirectly via protein complex interaction)Other (roles are primarily regulatory or modulatory in disease contexts)
05

Safety considerations

None known; not a direct therapeutic target, and thus no prominent drug-related safety concerns
06

Interacting drugs

None directly established; ATXN1L is not a primary drug target
07

Biomarkers

None established for patient selection or therapeutic efficacy; no clinical validation as a biomarker

Beyond the preview

Go deeper on Ataxin-1-like (ATXN1L).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ataxin-1-like (ATXN1L).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call